HEADER HYDROLASE/HYDROLASE INHIBITOR 17-JAN-99 1B6P TITLE HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 7 COMPND MOL_ID: 1; COMPND 2 MOLECULE: RETROPEPSIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: HIV-1 PR; COMPND 5 EC: 3.4.23.16; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 OTHER_DETAILS: CYS RESIDUES REPLACED WITH ABA KEYWDS COMPLEX (ACID PROTEINASE-PEPTIDE), HYDROLASE-HYDROLASE INHIBITOR KEYWDS 2 COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR J.L.MARTIN,J.BEGUN,A.SCHINDELER,W.A.WICKRAMASINGHE,D.ALEWOOD, AUTHOR 2 P.F.ALEWOOD,D.A.BERGMAN,R.I.BRINKWORTH,G.ABBENANTE,D.R.MARCH, AUTHOR 3 R.C.REID,D.P.FAIRLIE REVDAT 5 15-NOV-23 1B6P 1 REMARK REVDAT 4 09-AUG-23 1B6P 1 REMARK LINK REVDAT 3 24-FEB-09 1B6P 1 VERSN REVDAT 2 01-APR-03 1B6P 1 JRNL REVDAT 1 07-JAN-00 1B6P 0 JRNL AUTH J.L.MARTIN,J.BEGUN,A.SCHINDELER,W.A.WICKRAMASINGHE, JRNL AUTH 2 D.ALEWOOD,P.F.ALEWOOD,D.A.BERGMAN,R.I.BRINKWORTH, JRNL AUTH 3 G.ABBENANTE,D.R.MARCH,R.C.REID,D.P.FAIRLIE JRNL TITL MOLECULAR RECOGNITION OF MACROCYCLIC PEPTIDOMIMETIC JRNL TITL 2 INHIBITORS BY HIV-1 PROTEASE. JRNL REF BIOCHEMISTRY V. 38 7978 1999 JRNL REFN ISSN 0006-2960 JRNL PMID 10387041 JRNL DOI 10.1021/BI990174X REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.851 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0010 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 86.0 REMARK 3 NUMBER OF REFLECTIONS : 11099 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.185 REMARK 3 FREE R VALUE : 0.240 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.400 REMARK 3 FREE R VALUE TEST SET COUNT : 1149 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.007 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.12 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 81.30 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1508 REMARK 3 BIN R VALUE (WORKING SET) : 0.2340 REMARK 3 BIN FREE R VALUE : 0.2860 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 11.90 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 203 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.020 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1480 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 63 REMARK 3 SOLVENT ATOMS : 99 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 4.70 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 17.60 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.00000 REMARK 3 B22 (A**2) : 0.00000 REMARK 3 B33 (A**2) : 0.00000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.20 REMARK 3 ESD FROM SIGMAA (A) : 0.21 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.27 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.26 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 BOND ANGLES (DEGREES) : 1.300 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 26.80 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.150 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.450 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.140 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.390 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.560 ; 2.500 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDXJA11R.PRO REMARK 3 PARAMETER FILE 2 : PARAM19.SOL REMARK 3 PARAMETER FILE 3 : NULL REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDXJA11R.PRO REMARK 3 TOPOLOGY FILE 2 : TOPH19.SOL REMARK 3 TOPOLOGY FILE 3 : INHIBTOP.INP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1B6P COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-JAN-99. REMARK 100 THE DEPOSITION ID IS D_1000000314. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 01-SEP-96 REMARK 200 TEMPERATURE (KELVIN) : 289 REMARK 200 PH : 5.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : YALE MIRRORS REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IIC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11387 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 86.0 REMARK 200 DATA REDUNDANCY : 2.400 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.09000 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 8.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 81.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.21600 REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: OTHER REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: PDB ENTRY 1CPI REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.22 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.17 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1 M ACETATE BUFFER PH 5.5 AND 30-60% REMARK 280 AMMONIUM SULFATE REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.62000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 30.93000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.45000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 30.93000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.62000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.45000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5510 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9040 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -58.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 18 CG CD OE1 NE2 REMARK 470 GLU A 35 CG CD OE1 OE2 REMARK 470 LYS A 41 CG CD CE NZ REMARK 470 LYS A 43 CG CD CE NZ REMARK 470 LYS A 70 CG CD CE NZ REMARK 470 LYS B 107 CG CD CE NZ REMARK 470 LYS B 141 CG CD CE NZ REMARK 470 LYS B 143 CG CD CE NZ REMARK 470 GLN B 161 CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO B 109 74.71 -69.88 REMARK 500 PRO B 179 82.89 -66.56 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 503 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE PI7 A 201 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1B6J RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 1 REMARK 900 RELATED ID: 1B6K RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 5 REMARK 900 RELATED ID: 1B6M RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 6 REMARK 900 RELATED ID: 1B6N RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 3 REMARK 900 RELATED ID: 1B6O RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 2 REMARK 900 RELATED ID: 1B6L RELATED DB: PDB REMARK 900 HIV-1 PROTEASE COMPLEXED WITH MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 4 DBREF 1B6P A 1 99 UNP P03369 POL_HV1A2 57 155 DBREF 1B6P B 101 199 UNP P03369 POL_HV1A2 57 155 SEQADV 1B6P ABA A 67 UNP P03369 CYS 123 SEE REMARK 999 SEQADV 1B6P ABA A 95 UNP P03369 CYS 151 SEE REMARK 999 SEQADV 1B6P ABA B 167 UNP P03369 CYS 123 SEE REMARK 999 SEQADV 1B6P ABA B 195 UNP P03369 CYS 151 SEE REMARK 999 SEQADV 1B6P LYS A 7 UNP P03369 GLN 63 SEE REMARK 999 SEQADV 1B6P ILE A 33 UNP P03369 LEU 89 SEE REMARK 999 SEQADV 1B6P LYS B 107 UNP P03369 GLN 63 SEE REMARK 999 SEQADV 1B6P ILE B 133 UNP P03369 LEU 89 SEE REMARK 999 SEQADV 1B6P GLN A 18 UNP P03369 GLN 74 SEE REMARK 999 SEQADV 1B6P GLU A 35 UNP P03369 GLU 91 SEE REMARK 999 SEQADV 1B6P LYS A 41 UNP P03369 LYS 97 SEE REMARK 999 SEQADV 1B6P LYS A 43 UNP P03369 LYS 99 SEE REMARK 999 SEQADV 1B6P LYS A 70 UNP P03369 LYS 126 SEE REMARK 999 SEQADV 1B6P LYS B 107 UNP P03369 LYS 63 SEE REMARK 999 SEQADV 1B6P LYS B 141 UNP P03369 LYS 97 SEE REMARK 999 SEQADV 1B6P LYS B 143 UNP P03369 LYS 99 SEE REMARK 999 SEQADV 1B6P GLN B 161 UNP P03369 GLN 117 SEE REMARK 999 SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET ASN LEU PRO SEQRES 4 A 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 A 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ABA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 ARG ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET ASN LEU PRO SEQRES 4 B 99 GLY LYS TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE PRO VAL GLU SEQRES 6 B 99 ILE ABA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ABA THR LEU ASN PHE MODRES 1B6P ABA A 67 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1B6P ABA A 95 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1B6P ABA B 167 ALA ALPHA-AMINOBUTYRIC ACID MODRES 1B6P ABA B 195 ALA ALPHA-AMINOBUTYRIC ACID HET ABA A 67 6 HET ABA A 95 6 HET ABA B 167 6 HET ABA B 195 6 HET SO4 A 502 5 HET SO4 A 503 5 HET PI7 A 201 52 HET SO4 B 501 5 HETNAM ABA ALPHA-AMINOBUTYRIC ACID HETNAM SO4 SULFATE ION HETNAM PI7 N-[3-(8-SEC-BUTYL-7,10-DIOXO-2-OXA-6,9-DIAZA- HETNAM 2 PI7 BICYCLO[11.2.2] HEPTADECA-1(16),13(17),14-TRIEN-11- HETNAM 3 PI7 YAMINO)-2-HYDROXY-1-(4-HYDROXY-BENZYL) -PROPYL]-3- HETNAM 4 PI7 METHYL-2-PROPIONYLAMINO-BUTYRAMIDE HETSYN PI7 MACROCYCLIC PEPTIDOMIMETIC INHIBITOR 7 FORMUL 1 ABA 4(C4 H9 N O2) FORMUL 3 SO4 3(O4 S 2-) FORMUL 5 PI7 C36 H53 N5 O7 FORMUL 7 HOH *99(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 186 THR B 191 1 6 HELIX 3 3 GLN B 192 GLY B 194 5 3 SHEET 1 A 4 GLN A 2 THR A 4 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 198 SHEET 4 A 4 GLN B 102 THR B 104 -1 N ILE B 103 O LEU A 97 LINK C ILE A 66 N ABA A 67 1555 1555 1.33 LINK C ABA A 67 N GLY A 68 1555 1555 1.33 LINK C GLY A 94 N ABA A 95 1555 1555 1.33 LINK C ABA A 95 N THR A 96 1555 1555 1.33 LINK C ILE B 166 N ABA B 167 1555 1555 1.33 LINK C ABA B 167 N GLY B 168 1555 1555 1.33 LINK C GLY B 194 N ABA B 195 1555 1555 1.33 LINK C ABA B 195 N THR B 196 1555 1555 1.33 SITE 1 AC1 5 GLY A 68 LYS A 70 PRO B 101 LYS B 155 SITE 2 AC1 5 HOH B 375 SITE 1 AC2 4 PRO A 1 ARG A 57 HIS A 69 HOH A 352 SITE 1 AC3 7 ARG A 14 GLY A 17 HOH A 350 HOH A 367 SITE 2 AC3 7 GLY B 116 GLY B 117 HOH B 314 SITE 1 AC4 25 ARG A 8 ASP A 25 GLY A 27 ASP A 29 SITE 2 AC4 25 VAL A 32 GLY A 48 GLY A 49 ILE A 50 SITE 3 AC4 25 PRO A 81 VAL A 82 ILE A 84 HOH A 301 SITE 4 AC4 25 HOH A 377 ARG B 108 ASP B 125 GLY B 127 SITE 5 AC4 25 ASP B 129 ASP B 130 VAL B 132 ILE B 147 SITE 6 AC4 25 GLY B 148 GLY B 149 ILE B 150 PRO B 181 SITE 7 AC4 25 ILE B 184 CRYST1 51.240 58.900 61.860 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019516 0.000000 0.000000 0.00000 SCALE2 0.000000 0.016978 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016165 0.00000